Heterogeneous Dose-Escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: An Institutional Phase 2 Study

Abstract

apy as a boost to external beam radiation. The use of brachytherapy declined over time from 62.9% in 2004 to 51.3% in 2012 (P<0.001). This decline was noted in both academic facilities (from 60.8% in 2004 to 47.0% in 2012, P<0.001) as well as in non-academic facilities (from 63.7% in 2004 to 53.0% in 2012, P<0.001). The use of intensity modulated radiation therapy increased during this same time period from 18.4% in 2004 to 38.2% in 2012 (P<0.001). On multivariate analysis, treatment at an academic center (OR 0.89, 95% CI 0.87-0.92, P<0.001), increasing age, and years of diagnosis from 2006-2012 were significantly associated with reduced brachytherapy usage. Conclusion: In this hospital-based registry, prostate brachytherapy usage has declined for low risk prostate cancer as intensity modulated radiation therapy usage has increased. However, it still remains the treatment of choice for 51.3% of patients as of 2012.